Abstract: The present disclosure relates to dosage forms for extended release of an antibody or large protein. The extended release dosage forms comprise a biodegradable multi-block copolymer matrix and provide for extended release of antibody or large protein over a desired time period.

Abstract: A method for purifying a target protein from a cell culture sample containing the target protein, viral compounds and other impurities, by affinity chromatography virus inactivation and optionally other purifications the affinity chromatography involving a) loading an affinity chromatography column with the cell culture sample thereby binding the target protein to the affinity chromatography column; b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is disaccharides, polyols or poly (ethylene glycol) polymers; c) collecting one or more fractions containing the target protein obtained from (b); d) potentially combining the fractions obtained from (c) to form an elution product pool, and wherein the virus inactivation involves e) incubating the elution product pool at a pH from 2.5 to 4.5.

Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity, which is induced by the addition of at least camphorsulfonic acid. The contained proteins in the prepared formulations are stabilized against aggregation and denaturation and are thus sufficiently storage-stable until administration to the patient.

Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity.

Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity. The contained proteins in the prepared formulations are stabilized against aggregation and denaturation and are thus sufficiently storage-stable until administration to the patient.

Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity.

Abstract: The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular disease, the use of HEBP-1 for the detection of a component of eNOS signal transduction, and the use of HEBP1 for the regulation of eNOS promoter activity.

Abstract: The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular disease, the use of HEBP-1 for the detection of a component of eNOS signal transduction, and the use of HEBP1 for the regulation of eNOS promoter activity.